Davis Polk advised Oryzon Genomics, S.A. on its private placement of approximately 7,273,000 of its ordinary shares pursuant to a capital increase. The offering consisted of two tranches: a Spanish tranche offered to investors in Spain and an international tranche offered to institutional investors in the United States and Europe. Gross proceeds from the offering were approximately €20 million.

Oryzon is a clinical-stage biopharmaceutical company focused on epigenetic therapies for cancer and neurodegenerative disorders.

The Davis Polk corporate team included partner Michael J. Willisch and associates Joshua S. Sills and Jose Lucena-Rebollo. Associate Matthew R. Silver provided 1940 Act advice. Members of the Davis Polk team are based in the Madrid and New York offices.

Copy link to share post